SRPT · Sarepta Therapeutics, Inc.

Current Thesis

The narrative leg on offer is survival converting into self-funding. After the 2025 acute-liver-failure deaths in non-ambulatory ELEVIDYS patients and the July 2025 US shipment pause, the open question was whether Sarepta could fund itself at all. The 2026-08-05 Q2 print answered a narrower version of it: total revenue $401.3M (down 34% year over year), net product revenue $328.7M, non-GAAP diluted EPS $0.64, GAAP and non-GAAP operating profitability, and cash and investments of $945.0M after a $197M build in the quarter. What is being bought is a durable exon-skipping annuity plus contract-manufacturing and Roche collaboration revenue paying for an siRNA pipeline — an ELEVIDYS recovery is explicitly not part of it, since management guided Q3 ELEVIDYS revenue below the Q2 figure of $98.1M.

The narrative is maturing — the turnaround has been the story since the 2026-08-05 print, the flow behind it has thinned to a single 2026-08-27 options-flow listicle in the 30 days that followed, and sell-side coverage sits at Hold with a consensus average target of $25.24 against the 2026-09-04 close of $22.50. The shares are up 44.7% over three months and sit 8.0% under the $24.45 52-week high with RSI(14) at 70.1, and the company's own next dated proof point is guided only to "2H 2026".

Bullish and bearish views on Sarepta Therapeutics, Inc.

The model's bull view on Sarepta Therapeutics, Inc. (SRPT), in brief: Q2 2026 (reported 2026-08-05): GAAP and non-GAAP operating profitability on $401.3M total revenue, with non-GAAP diluted EPS of $0.64. The bear view: ELEVIDYS contributed $98.1M of Q2 net product revenue and management guided Q3 lower still; the flagship is shrinking on a guided path, not stabilising on one. Both cases follow in full.

Bull Case

• Q2 2026 (reported 2026-08-05): GAAP and non-GAAP operating profitability on $401.3M total revenue, with non-GAAP diluted EPS of $0.64.
• Cash and investments of $945.0M, up $197M inside the quarter — the balance sheet is building, not draining, through the post-crisis reset.
• The PMO franchise produced $230.6M in Q2, the part of the P&L untouched by the AAV safety question.
• sNDAs converting AMONDYS 45 and VYONDYS 53 from accelerated to traditional approval have been accepted, with a PDUFA target action date of 2027-02-28 — the confirmatory-evidence overhang on the annuity has a scheduled end.
• 2026 collaboration and other revenue guidance was raised to $550–600M on contract manufacturing and Roche milestones, a line that grew while product revenue shrank.
• Management said on the 2026-08-05 call that ELEVIDYS enrollment-form activity improved quarter over quarter, and that the enrollment-to-infusion journey runs roughly six months — a lead indicator that precedes revenue by two quarters.
• DM1 and FSHD siRNA multiple-ascending-dose data are guided to 2H 2026, the first human proof point for the platform the company pivoted toward.
• Wolfe Research upgraded to Outperform with a $27 target in July 2026.

Bear Case

• ELEVIDYS contributed $98.1M of Q2 net product revenue and management guided Q3 lower still; the flagship is shrinking on a guided path, not stabilising on one.
• Full-year net product revenue guidance was narrowed to $1.2–1.3B from $1.2–1.4B on 2026-08-05 — the top end was removed.
• The ELEVIDYS Cohort 8 12-week safety readout moved to Q1 2027. The single datapoint that would most directly rehabilitate the gene therapy sits two quarters beyond the current window.
• Non-GAAP operating expense guidance of $800–850M against $1.2–1.3B of product revenue means the reported profitability leans on the $550–600M collaboration line, which is milestone- and manufacturing-driven and does not annualise cleanly.
• Consensus across 25 analysts is Hold with an average target of $25.24; The published sell-side band brackets the current price rather than pointing above it.
• RSI(14) at 70.1 with the price 8.0% below the $24.45 52-week high, and no company-confirmed event dated inside the next 30 days.
• Hepatotoxicity is a permanent tail risk in AAV microdystrophin; one new fatal case would re-open the July 2025 question in a single session.

Setup & Price Structure

The 2026-09-04 close of $22.50 sits 8.0% below the $24.45 52-week high, and the entire trailing year traded under that high — the re-rate is a recovery off a wrecked base, so $24.45 is a ceiling built by a falling market rather than by a prior breakout. RSI(14) at 70.1 after a 44.7% three-month advance puts the tape in the extended half of its range without an event to price.

Crowding observables, stated as observables: RSI(14) 70.1; an 8.0% gap to the 52-week high after a 44.7% three-month move; the only name-specific coverage in the 30 days to 2026-09-04 was a 2026-08-27 Benzinga options-flow listicle, the retail-sentiment shape that typically appears late in a move rather than early; no Form 4 or 8-K appeared in the 30-day filing window reviewed, so there is no insider-sale or issuance evidence either way. Nothing in the structure argues the base has been rebuilt above $24.45; the gate is a weekly close through that level, and $19 is where the post-August advance would be given back.

Catalyst Calendar (next 30 days)

• 2026-09-05 to 2026-10-05: no company-confirmed dated event. This absence is the structural weakness of the setup — a maturing narrative with nothing scheduled to refresh it.
• ~2026-12-31 (est., company guide "2H 2026") — DM1 and FSHD siRNA MAD cohort data. First platform readout post-pivot.
• ~2026-11-04 (est.) — Q3 2026 results;
• 2027-02-28 — PDUFA target action date, AMONDYS 45 / VYONDYS 53 traditional-approval conversion.
• ~2027-03-31 (est., company guide "Q1 2027") — ELEVIDYS Cohort 8 12-week safety data; enrollment guided complete by end-2026.
• ~2027-03-31 (est., company guide "early next year") — first proof-of-biology data for SRP-1005 in Huntington's, from the INSIGHTT Phase 1.

What Would Change Our Mind

The structure that has to hold is the post-print advance itself, because nothing dated supports it between now and the Q3 report. A weekly close below $19 gives back the bulk of the move that followed the 2026-08-05 print and ends the recovery-leg read; at that point the tape has priced the guidance narrowing rather than the balance sheet.

Secondary conditions, any of which would break the fundamental leg independently: the 2H-2026 DM1/FSHD siRNA cohort data passing 2026-12-31 without a readout, which removes the only platform proof point inside the fiscal year; Q3 ELEVIDYS revenue landing materially under the $98.1M Q2 figure alongside a cut to the $1.2–1.3B product-revenue guide at the ~2026-11-04 print; or 2027 collaboration and other revenue guided below the 2026 $550–600M level, which would show the reported operating profitability was a milestone artefact.

What would strengthen it instead: a weekly close above $24.45 on siRNA cohort data, which would take the name out of its 52-week range for the first time since the crisis.

Correlation Notes

The Precision biotech & therapeutics cluster (OABI, ABCL, AMLX, CRDL, OMER, AQST, LIFE, ASMB, KYMR, CABA, FDMT) has read as maturing on the weekly trail since 2026-08-23, after a brief acceleration on 2026-08-16. That raises the bar here rather than supporting the name: SRPT is the only member guiding to more than $1B of product revenue, so its beta to the cluster is weaker than its beta to two other things — FDA stance on AAV gene therapy, and Roche, whose ex-US ELEVIDYS milestones flow directly into the $550–600M collaboration line. A cluster-wide bid would not by itself validate the SRPT thesis, and a cluster-wide drawdown would not by itself break it; the DM1/FSHD readout and the Q3 ELEVIDYS number are what settle it.

Within DMD specifically, any competitor safety event in AAV microdystrophin reads across immediately, in both directions — a clean competitor safety database supports the platform argument the Cohort 8 readout is meant to close in Q1 2027.